公开(公告)号：US08920800B2

公开(公告)日：2014-12-30

申请号：US13913292

申请日：2013-06-07

Applicant: Five Prime Therapeutics, Inc.

Inventor： Harold Keer

IPC: A61K39/00 ,  A61K38/00 ,  A61P35/00 ,  A61K39/395 ,  A61K38/17 ,  A61K45/06

CPC classification number: C07K16/22 ,  A61K38/179 ,  A61K39/3955 ,  A61K45/06 ,  C07K14/71 ,  C07K2319/30 ,  C07K2319/33

Abstract: The present invention provides methods of treating a patient having a cancer comprising administering to the patient a soluble Fibroblast Growth Factor Receptor 1 (FGFR1) fusion protein such as an extracellular domain of an FGFR1 polypeptide linked to an Fc polypeptide or another fusion partner. The fusion protein may be administered at a dose of at least about 2 mg/kg body weight. In some embodiments, the patient has a fibroblast growth factor-2 (FGF-2) plasma concentration of at least 6 pg/ml. In some embodiments, the cancer is characterized by a Fibroblast Growth Factor Receptor 2 (FGFR2) having a ligand-dependent activating mutation.

Abstract translation: 本发明提供了治疗患有癌症的患者的方法，包括向患者施用可溶性成纤维细胞生长因子受体1（FGFR1）融合蛋白，例如与Fc多肽或另一融合配偶体连接的FGFR1多肽的细胞外结构域。 融合蛋白可以以至少约2mg / kg体重的剂量施用。 在一些实施方案中，患者具有至少6pg / ml的成纤维细胞生长因子-2（FGF-2）血浆浓度。 在一些实施方案中，癌症的特征在于具有配体依赖性激活突变的成纤维细胞生长因子受体2（FGFR2）。

公开(公告)号：US20140322757A1

公开(公告)日：2014-10-30

申请号：US14266209

申请日：2014-04-30

Applicant: Five Prime Therapeutics, Inc.

Inventor： Justin Wong ,  Maximiliano Vasquez

IPC: C07K16/28

CPC classification number: C07K16/2866 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C12N15/11 ,  C12N15/63

Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.

Abstract translation: 提供了结合CSF1R的抗体。 还提供能够形成结合CSF1R的抗体的抗体重链和轻链。 提供编码CSF1R抗体的多核苷酸。 还提供了编码抗体重链和灯链的多核苷酸。 提供使用抗CSF1R抗体的方法。 这些方法包括但不限于治疗类风湿性关节炎，骨丢失和多发性硬化症的方法。

公开(公告)号：US20140140995A1

公开(公告)日：2014-05-22

申请号：US14048841

申请日：2013-10-08

Applicant: Five Prime Therapeutics, Inc.

Inventor： Lewis T. Williams ,  Elizabeth Bosch ,  Stephen K. Doberstein ,  Kevin Hestir ,  Diane Hollenbaugh ,  Ernestine Lee ,  Minmin Qin ,  Ali Sadra ,  Justin Wong ,  Ge Wu ,  Hongbing Zhang

IPC: A61K47/48 ,  A61K45/06

CPC classification number: C07K14/71 ,  A61K45/06 ,  C07K14/765 ,  C07K16/2863 ,  C07K17/08 ,  C07K2319/30 ,  C07K2319/32

Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.

Abstract translation: 本发明提供了FGFR融合蛋白，其制备方法以及使用它们来治疗增殖性疾病（包括癌症和血管生成障碍）的方法。 FGFR融合分子可以在CHO细胞中制备，并且可以包含改善其稳定性的FGFRs的细胞外结构域中的缺失突变。 这些融合蛋白体外和体内抑制癌细胞的生长和活力。 这些受体对其配体FGF的相对高亲和力的组合以及这些诱饵受体抑制肿瘤生长的证明的能力是本文提供的组合物和方法的临床价值的指示。

公开(公告)号：US20250164475A1

公开(公告)日：2025-05-22

申请号：US19028091

申请日：2025-01-17

Applicant: FIVE PRIME THERAPEUTICS, INC.

Inventor： Nallakkan Arvindan ,  Stephen Mehi ,  Guanqing Ou

IPC: G01N33/543 ,  B01F23/50 ,  G02B13/22 ,  G02B15/00 ,  G02B21/00 ,  G02B21/16 ,  G02B21/26

Abstract: An optical imaging system includes a frame designed to provide mechanical coupling between a first stage and a second stage, a sample holding region located on the first stage, a lens arrangement, and a sensor array. The lens arrangement is disposed between the first stage and the second stage and is designed to receive light from a sample at the sample holding region on the first stage. The lens arrangement has a numerical aperture less than 0.1. The sensor array is coupled to the second stage and is designed to receive light passing through the lens arrangement.

公开(公告)号：US12195535B2

公开(公告)日：2025-01-14

申请号：US18162991

申请日：2023-02-01

Applicant: Five Prime Therapeutics, Inc. ,  Bristol-Myers Squibb Company

Inventor： Robert J. Johnston ,  Arvind Rajpal ,  Paul O. Sheppard ,  Luis Borges ,  Andrew Rankin ,  Keith Sadoon Bahjat ,  Alan J. Korman ,  Andy X. Deng ,  Lin Hui Su ,  Ginger Rakestraw

IPC: C07K16/28

Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

公开(公告)号：US20240092907A1

公开(公告)日：2024-03-21

申请号：US18162991

申请日：2023-02-01

Applicant: Five Prime Therapeutics, Inc. ,  Bristol-Myers Squibb Company

Inventor： Robert J. Johnston ,  Arvind Rajpal ,  Paul O. Sheppard ,  Luis Borges ,  Andrew Rankin ,  Keith Sadoon Bahjat ,  Alan J. Korman ,  Andy X. Deng ,  Lin Hui Su ,  Ginger Rakestraw

IPC: C07K16/28

CPC classification number: C07K16/2812 ,  C07K2317/34 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

公开(公告)号：US20230416382A1

公开(公告)日：2023-12-28

申请号：US18248979

申请日：2021-10-13

Applicant: Five Prime Therapeutics, Inc.

Inventor： Susannah D. BARBEE ,  Shujun YUAN ,  Marcel MEURY ,  Alessandro PALUMBO ,  Terence WONG ,  Kathrin ZUBERBUHLER ,  Emilia FALKOWSKA

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2866 ,  A61P35/00 ,  C07K2317/565

Abstract: This present invention provides anti-C—C chemokine type 8 (CCR8) antibodies and antigen binding fragments thereof, methods of making the antibodies or antigen binding fragments thereof, and methods of use thereof to bind to human CCR8 on CCR8 expressing cells, e.g., tumor-infiltrating Treg cells, to remove CCR8 expressing cells, e.g, tumor-infiltrating Treg cells, to reduce or inhibit tumor growth and/or to treat cancer.

公开(公告)号：US11603406B2

公开(公告)日：2023-03-14

申请号：US16493712

申请日：2018-03-13

Applicant: Five Prime Therapeutics, Inc. ,  Bristol-Myers Squibb Company

Inventor： Robert J. Johnston ,  Arvind Rajpal ,  Paul O. Sheppard ,  Luis Borges ,  Andrew Rankin ,  Keith Sadoon Bahjat ,  Alan J. Korman ,  Andy X. Deng ,  Lin Hui Su ,  Ginger Rakestraw

IPC: C07K16/28

Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

公开(公告)号：US20230052212A1

公开(公告)日：2023-02-16

申请号：US17818256

申请日：2022-08-08

Applicant: FIVE PRIME THERAPEUTICS, INC.

Inventor： Kristen PIERCE ,  Janine POWERS ,  Servando PALENCIA ,  Robert SIKORSKI ,  Majid GHODDUSI ,  Kartik KRISHNAN

IPC: C07K16/28 ,  G01N33/50 ,  G01N33/574 ,  C07K16/30

Abstract: Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1. In some embodiments, FGFR2 inhibitors may comprise FGFR2 antibodies or FGFR2 extracellular domain (ECD) polypeptides, or FGFR2 ECD fusion molecules comprising an FGFR2 ECD and a fusion partner. In some embodiments, PD-1/PD-L1 inhibitors may comprise anti-PD-1 antibodies such as antibodies that bind to PD-1 or to PD-L1 and inhibit interactions between these proteins, as well as PD-1 fusion proteins or polypeptides.

公开(公告)号：US20220298258A1

公开(公告)日：2022-09-22

申请号：US17695081

申请日：2022-03-15

Applicant: Bristol-Myers Squibb Company ,  Five Prime Therapeutics, Inc.

Inventor： Robert J. Johnston ,  Andrew Rankin ,  Arathi Krishnakumar ,  Paul O. Sheppard ,  Arvind Rajpal

IPC: C07K16/28

Abstract: Methods of identifying and using PSGL-1 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer. PSGL-1 antagonists include, but are not limited to, antibodies that bind PSGL-1 and antibodies that bind VISTA, wherein the antibodies inhibit PSGL-1 binding to VISTA, e.g., at acidic pH (e.g., pH 6.0), as well as PSGL-1 and VISTA extracellular domain polypeptides.